PitchBook：2025年二季度医疗技术公共报表和估值指南报告（英文版）

Medtech outpaces broader market: Public medtech firms outperformed broad indexes for the second straight quarter, with all medtech subsectors posting median double-digit share price gains or higher—compared with a 9.7% gain for the S&P 500. Leading the pack were Tempus AI and Exact Sciences, with share price increases of 58% and 57%, respectively, as investors flocked to higher-risk, higher-reward diagnostic companies. Tempus shares have now climbed nearly 50% since the firm’s IPO in June